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a  b  s  t  r  a  c  t
Chlamydia  trachomatis  infection  is  one  of the  most  prevalent  bacterial  STIs  in the  USA
and  worldwide,  and  women  with  C.  trachomatis  infection  are  at increased  risk  of acquir-
ing HIV.  Because  immune  activation  at the  genital  mucosa  facilitates  HIV/SIV  infection,
C.  trachomatis-mediated  cytokine  induction  may  contribute  to  increased  HIV transmis-
sion  in asymptomatic  women.  To  begin  to  elucidate  the  mechanisms,  we  longitudinally
analyzed  proﬁles  of  innate  immune  factors  and  HIV  infectivity  in genital  secretions  from
anatomically  speciﬁc  sites  in  asymptomatic  women  during  C.  trachomatis  infection  and
post-antibiotic  treatment.  We  found  higher  levels  of cytokines  and  chemokines  in endo-
cervical  secretions  than  vaginal  secretions.  Compared  with  the  convalescent  state,  G-CSF,
IL-1, and  RANTES  were  elevated  in endocervical  secretions,  IFN-  and  TNF-  were  ele-
vated  in  vaginal  secretions,  and  IFN,  IL-1,  and  MIP1-  were  elevated  in cervicolavage
ﬂuid  (CVL),  before  adjustment  of multiple  comparisons.  Elevated  endocervical  levels  of  IP-
10 and  MCP-1  were  associated  with  the  use  of hormonal  contraception  in  infected  women
after successful  treatment,  suggesting  the  role  of  hormonal  contraception  in  inﬂammation
independent  of  STIs.  Importantly,  soluble  factors  found  in  endocervical  secretions  during
infection  enhanced  HIV  infectivity  while  no difference  in  HIV  infectivity  was  found  with
vaginal  secretions  or CVL  during  infection  or at convalescence.  Taken  together,  the  proﬁles
of immune  mediators  and  in vitro  HIV  infectivity  indicate  that  the endocervical  and  vaginal
mucosa  are  immunologically  distinct.  Our results  underscore  the  importance  of consider-
ing anatomical  site  and  local  sampling  methodology  when  measuring  mucosal  responses,
particularly  in  the  presen
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1. Introduction
Sexually transmitted infections (STIs) are known to
increase the likelihood of HIV transmission (Galvin and
Cohen,  2004; Plummer, 1998; Cohen et al., 1997; Chesson
and  Pinkerton, 2000; Mabey, 2000). Chlamydia trachomatis
infection is the most frequently reported bacterial STI in the
United  States (Centers for Disease Control and Prevention,
2010). C. trachomatis infection can lead to pelvic inﬂam-
matory disease and infertility in women without treatment
(Arora et al., 1992; Pal et al., 1998). Over 70% of women with
C.  trachomatis infection are asymptomatic (Brunham and
Rey-Ladino, 2005); hence, the majority of C. trachomatis-
infected women remain undiagnosed/untreated and are a
population  at increased risk of acquiring HIV.
In women, C. trachomatis primarily infects the endo-
cervix (Brunham and Rey-Ladino, 2005), which is also a
portal  of entry for HIV/SIV (Li et al., 2009; Haase, 2005).
C.  trachomatis induces robust production of proinﬂam-
matory cytokines including IL-8, IL-6, and IL-1 in HeLa
cells  (an adenocarcinoma cell line from the cervix), but only
a  very modest induction in endocervical (A2EN cell line)
and  endometrial epithelial cells (HEC-1B adenocarcinoma
cell line) (Rasmussen et al., 1997; Dessus-Babus et al., 2000;
Buckner  et al., 2011a). In C. trachomatis-positive, infertile
women (aged 20–38), the levels of IFN-, TNF-, IL-10,
and IL-12 are up-regulated in cervical secretions (Reddy
et  al., 2004). Speciﬁc cytokine induction can have an impact
on  the recruitment of lymphocytes such as CD4+ T cells
and  their cell surface marker expression. Indeed, increased
numbers of endocervical CD4+ T cells have been found in
C.  trachomatis-infected women (Mittal et al., 2004; Ficarra
et  al., 2008; Levine et al., 1998). The endocervical cell inﬁl-
trate  from C. trachomatis-infected women is dominated by
activated  effector memory T cells with elevated levels of
CCR5  expression (Ficarra et al., 2008; Schust et al., 2012;
Ibana et al., 2012), which can serve as an ideal HIV target.
Because immune activation at the genital mucosa
facilitates HIV/SIV infection (Haase, 2010), C. trachomatis
infection may  contribute to increased HIV transmission in
untreated  women. In this pilot study, we analyzed pro-
ﬁles  of innate immune factors in genital secretions from
anatomically speciﬁc sites in women during C. trachomatis
infection pre- and post-antibiotic treatment. Their inﬂu-
ence  on HIV infectivity was also investigated in vitro. Our
results  indicate that endocervical and vaginal secretions of
C.  trachomatis-infected young women exhibit differential
cytokine/chemokine proﬁles and differential effects on HIV
infectivity.  This underscores the importance of appropri-
ate  sampling of different sites in the female genital tract to
understand how HIV is acquired and transmitted, particu-
larly  in the presence of STI co-infections.
2. Materials and Methods
2.1.  Study designInstitutional Review Board approvals for this study were
obtained from Mount Sinai School of Medicine and Rut-
gers  Biomedical and Health Sciences, New Jersey Medical
School. Participants were women attending the Mounte Immunology 99 (2013) 80– 87 81
Sinai  Adolescent Health Center, which provides C. tracho-
matis  screening as part of routine care for all sexually
active adolescents and young adults. C. trachomatis-
positive women, who met  the primary screening criteria
as  described below and who were willing to participate
in the study, signed the informed consent form and were
compensated.
The  enrollment eligibility criteria were as follows:
(1) Healthy, non-pregnant women  aged 18–26;
(2)  Positive nucleic acid ampliﬁcation screening test for C.
trachomatis;
(3) If postpartum, at least six weeks postpartum and at
least one normal menstrual cycle since delivery;
(4)  No recent antibiotic treatment (within seven days of
enrollment examination);
(5) No known or suspected HIV-1 infection;
(6)  No antibiotic allergies to azithromycin (standard treat-
ment);
(7) No known or suspected immunosuppressive illnesses
or conditions (e.g., history of splenectomy, history of
auto-immune disorders (systemic lupus erythemato-
sus or rheumatoid arthritis), or history of requiring
chronic  systemic immunosuppressive therapy;
(8)  No sexual intercourse for 24 h before enrollment visit
and willingness to abstain from sexual intercourse for
24 h before follow-up visits, and;
(9)  Able to give informed consent.
If a participant did not fulﬁll one of the inclusion criteria
after the initial session, their samples were excluded from
the  primary study analysis and they were not invited for
subsequent research visits.
Sexually  transmitted pathogens including C. tracho-
matis, Neisseria gonorrhoeae, Trichomonas vaginalis, HPV,
and  HSV2 were determined by DNA testing using BD
ProbeTecTM collection kits with the BD ViperTM System.
Samples were taken after collection of endocervical and
vaginal  secretions as described below. Bacterial vaginosis
(BVs) was  diagnosed based on the Amsel clinical criteria,
which includes an elevated vaginal pH, a positive KOH
“whiff test,” clue cells on light microscopy, and appearance
of  the vaginal discharge. Vaginal pH was measured by using
S/P  pH indicator strips with pH range of 3.6–6.1 (Cardinal
Health, McGaw, IL, USA).
Endocervical and vaginal secretions were collected
using Merocel ophthalmic sponges (#405101, Medtronic
Xomed, Inc, Jacksonville, FL, USA) (Castle et al., 2004) from
women  with positive screening tests for C. trachomatis
on enrollment and again approximately four weeks after
standard antibiotic treatment (azithromycin 1 g orally in a
single  dose). For endocervical secretions, the sponge was
placed  in the cervical os for 30 s. The vaginal sample was
collected by a 360◦ sweep of the mid-vaginal wall. Sponges
were immediately immersed in 0.7 ml  of Keratinocyte-
SFM (Invitrogen). Cervicovaginal lavage (CVL) in 10 ml of
saline  was also collected. After centrifugation, supernatants
were aliquoted and stored at −80 ◦C before analysis. To
analyze pretreatment and post-treatment samples at the
same  time, these samples underwent one freeze–thaw
cycle. Samples were analyzed within 12 months of the
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Table 1
Patient characteristics.
Patients Race/ethnicity Age Hormonal contraceptive pH pre-treatment pH post-treatment
1 Black/Hispanic 18 None 5.0 5.5
2  Black 19 None 5.0 4.4
3  White/Hispanic 19 NuvaRing 4.4 4.4
4  Black 21 NuvaRing 5.0 4.9
5 Black 18 None 5.0 4.7
6  Hispanic 18 Pill 5.3 4.4
7  Black 20 None 5.5 4.4
8  Black/White/Chinese/Caribbean 19 None 5.5 4.8
9  Hispanic 22 Pill 5.5 5.0
10  Hispanic 20 None 4.3 4.1
11  Black 19 None 4.4 4.1
12  Hispanic 20 NuvaRing 5.0 4.3





































a14  Hispanic 21 N
15  Hispanic 22 N
A: not available.
rst specimen being collected. Protein concentrations of
ervicovaginal secretions were determined by the Bradford
ssay  (Bio-Rad, Hercules, CA, USA).
.2. HIV infectivity assay
Pseudotyped  HIV-1JR-FL luciferase reporter viruses were
roduced as described previously (Connor et al., 1997;
hen et al., 1994). The effect of cervicovaginal secretions
n HIV infectivity was analyzed by a single-cycle infec-
ion  assay (Klotman et al., 2008). Cervicovaginal secretions
id  not exert any effect on proliferation of HeLa-CD4-CCR5
ells after two hour incubation as determined by MTS  assay
Promega). HeLa-CD4-CCR5 cells (clone: JC48) were a gift
rom  David Kabat. Endocervical and vaginal secretions from
he  swabs were diluted 1:5 with K-SFM and then incubated
ith R5 HIV-1JR-FL luciferase reporter virus for one hour
t  37 ◦C before addition to HeLa-CD4-CCR5 cells for addi-
ional  two hours. CVL was not diluted before incubation
ith virus in the HIV infectivity assay. Cells were washed
ith PBS to remove unbound virus and incubated for two
ays  before measuring luciferase activity in the target cells.
.3.  Cytokine/chemokine analysis
Cytokines and chemokines were analyzed using a
uminex 200 (Luminex, Austin, TX, USA) and Millipore
ultiplex kits (Billerica, MA,  USA). Results were analyzed
sing Millipore Analyst software. Limit of detection (sen-
itivity)  of each analyte is as follows: G-CSF (3.2 pg/ml),
FN (0.5 pg/ml), IL-1 (3.2 pg/ml), IL-1 (0.45 pg/ml),
L-6 (0.11 pg/ml), IL-8 (3.2 pg/ml), IL-10 (0.38 pg/ml), IP-
0  (3.2 pg/ml), MCP-1 (3.2 pg/ml), MIP-1 (3.2 pg/ml),
ANTES (0.3 pg/ml), TNF (0.2 pg/ml). The choice of these
ytokines and chemokines was based on our previous study
Kraus  et al., 2010) and the initial screening.
.4. Statistical analysisDifferences  in pH, cytokines, chemokines, and HIV infec-
ivity  pre- and post-antibiotic treatment were examined
sing Wilcoxon signed-rank tests. Differences in cytokines
nd  chemokines between contraceptive users andg 3.7 4.6
5.6 NA
non-contraceptive users were examined using Wilcoxon
rank-sum tests. Multiple comparisons were adjusted by
false  discovery rates. All statistical analyses were per-
formed using SAS Version 9.2 (SAS Inc., Cary, NC, USA).
All  P values were two-tailed, with P < 0.05 considered to
indicate  statistical signiﬁcance.
3.  Results
3.1. Patient characteristics
A  total of 19 C. trachomatis subjects meeting the eligi-
bility criteria were enrolled into the study, and of these,
15  subjects were included in the ﬁnal analysis. One sub-
ject  was excluded because of a positive chlamydia test at
the  follow-up (post-treatment) visit, and the other three
subjects did not return for a follow-up visit. As expected,
according to the demographic characteristics of the recruit-
ment  clinic, all subjects were black or Hispanic with a mean
age  of 19.6 ± 1.4 (Table 1). Seven women  (47%) were using
hormonal contraception at the time of sample collection.
The median vaginal pH at the ﬁrst visit (C. trachomatis-
positive; median 5.0, range 3.7–5.6) was slightly albeit not
signiﬁcantly higher than the pH of samples from subjects
post-treatment (median 4.4, range 4.1–5.5; P = 0.074).
The prevalence of laboratory-diagnosed STIs or BVs in
these  young women  at the enrollment was  not as high as
a  previous report on a cohort of high-risk women  (Mlisana
et  al., 2012). Of 15 C. trachomatis-positive subjects, one
woman  had T. vaginalis, ﬁve (33%) had HPV, two  (13%)
had  HSV-2, and four (27%) had BVs (Table 2). None of the
women  was  positive for N. gonorrhoeae infection. Note that
azithromycin regimen was  prescribed for treating C. tra-
chomatis infection and would not have an effect on BVs
(Schwebke and Desmond, 2007).
3.2. Cytokines/chemokine proﬁles of cervicovaginal
secretions from C. trachomatis-infected women pre- and
post-antibiotic treatmentOverall,  the levels of cytokines and chemokines were
signiﬁcantly higher in endocervical secretions than in
vaginal  secretions or CVL (Tables 3–5). IL-10 and RANTES
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Table  2
Concurrent sexually transmitted infections and bacterial vaginosis in patients before treatment.
Patients CT Previous CT history GC Trich BV HPV HSV2
1 + No − − − − −
2  + No − − − − −
3  + 5 months − − − − −
4  + No − − − − −
5  + 22 months − − + − −
6  + No − + − − +
7  + 13 months − − + − −
8  + No − − − − −
9  + No − − + − −
10  + No − − − − −
11  + No − − − + −
12  + No − − + + −
13  + No − − − + −
14  + 24 months − − − + +
15  + 10 months − − − + −
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), Trichomonas vaginalis (Trich), bacterial vaginosis (BV), Human papillomavirus (HPV), Herpes simplex
virus-2  (HSV-2).
Table  3
The  levels of cytokines/chemokines in endocervical samples from women  with chlamydial infection pre- and post-treatment.
Cytokines/chemokines Pre-treatment median, (IQR), pg/ml Post-treatment median (IQR), pg/ml P  value Adjusted *P value
G-CSF 4516.5 (2147–8457) 2345.5 (1544–3477) 0.007 0.042
IFN 13.5 (3.6–33.1) 5.4 (4.0–14.0) 0.194 0.259
IL-10 16.5 (7.8–35.5) 7.9 (2.9–18.2) 0.077 0.156
IL-6 251.6 (62.7–435.6) 122.3 (75.4–280) 0.091 0.156
IL-8 1357.5 (651–4337.3) 896.2 (392–2940) 0.463 0.505
IL-1 342.3 (93–649) 76.1 (25.4–122.4) 0.007 0.042
IL-1 6.4 (1.6–31.7) 2.95 (1.7–3.8) 0.068 0.156
IP-10 2492.9 (322–9793.5) 980 (309–1407) 0.091 0.156
MCP-1 681.4 (165.7–1378.9) 408 (192.6–778.8) 0.583 0.583
MIP-1 37.3 (13.6–92.2) 10.9 (3.2–40.3) 0.380 0.456
TNF 8.5 (4.2–15.3) 4.4 (3.5–5.9) 0.194 0.259
RANTES 79.8 (26.4–182.6) 20.1 (13.1–76.9) 0.022 0.088
There were no signiﬁcant differences in most cytokine and chemokine levels between hormonal contraceptive users and non-users in either pre- or post-
8.3–152
.043 (W
adjustedtreatment  women, except for IP-10 post-treatment, which was 561.9 (40
which  was 45.4 (3.2–95.3) for users and 5.4 (3.2–14.8) for non-users, P = 0
* P values were adjusted by false discovery rates for multiple tests. An 
were not detectable in vaginal secretions or CVL. The
levels of G-CSF, IL-1, and RANTES were signiﬁcantly
higher in pretreatment endocervical secretions than in
post-treatment endocervical secretions (Table 3, high-
lighted in gray, P < 0.05). Although endocervical levels of
IL-10,  IL-6, IL-1, and IP-10 were also elevated during
chlamydial infection, the difference between pre- and
post-treatment was not signiﬁcant (Table 3). In vaginal
Table 4
The  levels of cytokines/chemokines in vaginal samples from women  with chlamy
Cytokines/chemokines Pre-treatment median, (IQR), pg/ml Post-t
G-CSF 1186 (421–10956) 499 
IFN 2.74 (1.16–8.56) 1.
IL-6  12.10 (4.57–55.69) 15.
IL-8  453 (317–5585) 1030 
IL-1 513 (135–2473) 456 
IL-1 14.52 (1.56–88.22) 8.
IP-10 74.47 (21.35–1396) 233.
MCP-1 103.0 (11.35–220.0) 55.
MIP-1 18.72 (13.62–48.07) 18.
TNF 2.02 (0.20–9.97) 0.
IL-10 and RANTES were not detectable in vaginal specimens. No signiﬁcant diffe
TNF  were found in vaginal samples of hormonal contraceptive users and non-us
* P values were adjusted by false discovery rates for multiple tests. An adjusted2) for users and 215.3 (130.5–571.2) for non-users, P = 0.02), and MCP-1,
ilcoxon rank-sum test). IQR: interquartile range.
 P value < 0.05 was  considered signiﬁcant.
secretions, the levels of IFN- and TNF- were signiﬁcantly
higher in pre-treatment than post-treatment (Table 4,
highlighted in gray). IFN-, IL-1, and MIP-1 were signif-
icantly higher in pretreatment CVL than in post-treatment
CVL, whereas TNF- was  unchanged (Table 5, highlighted
in gray). Despite a pilot study with 15 subjects, multi-
ple comparisons were adjusted by false discovery rates
(Tables 3–5). After adjustment for multiple comparisons,
dial infection pre- and post-treatment.
reatment median, (IQR), pg/ml P value Adjusted *P value
(152–3055) 0.208 0.482
16 (1.16–2.22) 0.027 0.135
29 (4.41–90.34) 0.910 0.910
(407–7404) 0.241 0.482
(171–1751) 0.762 0.847
28 (1.23–54.98) 0.169 0.482
0 (60.85–492.0) 0.720 0.847
4 (25.52–140.0) 0.762 0.847
47 (14.93–24.46) 0.360 0.600
32 (0.2–1.92) 0.006 0.060
rences in G-CSF, IFN, IL-6, IL-8, IL-1, IL-1, IP-10, MCP-1, MIP-1, or
ers in either pre- or post-treatment women. IQR: interquartile range.
 P value < 0.05 was  considered signiﬁcant.
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Table 5
The  levels of cytokines/chemokines in CVL from women  with chlamydial infection before pre- and post-treatment.
Cytokines/chemokines Pre-treatment median, (IQR), pg/ml Post-treatment median, (IQR), pg/ml P value Adjusted *P value
G-CSF 643 (279–1223) 265 (103–440) 0.095 0.237
IFN 1.3 (1.2–2.3) 1.2 (0.9–1.2) 0.020 0.160
IL-6 4.1 (0.4–7.7) 0.9 (0.4–9.2) 0.638 0.709
IL-8 210 (51.6–366) 280 (92.3–582) 0.169 0.282
IL-1 393 (83–1159) 230 (45–547) 0.454 0.567
IL-1 8.5 (1.2–29.5) 4.3 (0.5–12.9) 0.043 0.160
IP-10 43.5 (17.4–174) 85 (22.7–247) 0.978 0.978
MCP-1 20.6 (3.6–34.0) 32.9 (10.4–78.1) 0.268 0.383
MIP-1 16.3 (14.3–22.7) 13.0 (10.9–18.2) 0.048 0.160
TNF 0.32 (0.2–3.62) 0.32 (0.2–0.32) 0.156 0.282
N P-1, MI







































to signiﬁcant differences in GCSF, IFN, IL-1, IL-1, IL-6, IL-8, IP-10, MC
on-users  in either pre- or post-treatment women. IL-10 and RANTES we
* P values were adjusted by false discovery rates for multiple tests. An 
-CSF and IL-1 in pretreatment endocervical secretions
emained signiﬁcantly higher than in post-treatment endo-
ervical  secretions. However, other cytokines/chemokines
n vaginal secretions and CVL were not signiﬁcantly dif-
erent.  Taken together, these results demonstrate that C.
rachomatis infection alters the expression pattern of many
ytokines and chemokines in the genital milieu, and that
natomically distinct regions of the female genital tract
ave  distinct proﬁles of these mediators. Thus, while C.
rachomatis infection primarily infects and has a signiﬁ-
ant  impact on cytokine responses in the endocervix, there
ppears  to be a more global inﬂammatory consequence of
nfection  that may  also encompass the lower genital tract.
Hormonal contraception plays an important role in
odulating innate immunity in the female genital tract
Hel  et al., 2010; Wira et al., 2010). Interestingly, we
bserved that the levels of cytokines and chemokines
ere generally not affected by hormonal contraceptive
se in either pre- or post-treatment samples. However,
n endocervical ﬂuid in the convalescent state, hormonal
ontraception use signiﬁcantly increased the expression of
P-10  and MCP-1 (Table 3).
.3. The effect of cervicovaginal secretions on HIV
nfectivity
The impact of endocervical secretions, vaginal sec-
etions, and CVL from C. trachomatis-positive women
re- and post-antibiotic treatment on HIV infectivity was
nvestigated using an R5 HIV-1JR-FL luciferase reporter as
escribed in the Section 2. Endocervical secretions from
.  trachomatis-positive women signiﬁcantly enhanced HIV
nfectivity  compared with samples from the same women
ost-treatment (Table 6). In contrast, antibiotic treatment
id  not change the effect of vaginal secretions or CVL on
IV  infectivity (Table 6). These results suggest that soluble
actors in endocervical secretions might contribute to the
ncreased  risk of HIV infection in C. trachomatis-infected
omen.
. DiscussionStudies on the vaginal transmission of SIV in the rhe-
us  macaque model indicate that the endocervix and
he  transformation zone are the preferential, though notP-1, and TNF were found in CVL of hormonal contraceptive users and
etectable in CVL. IQR: interquartile range.
 P value < 0.05 was  considered signiﬁcant.
exclusive,  sites for viral entry (Li et al., 2009; Haase, 2010;
Miller  et al., 1992). In this longitudinal study, we aimed to
determine the proﬁles of immune mediators in endocer-
vical and vaginal secretions from C. trachomatis-infected
women  and to examine the effect of these secretions on
HIV  infectivity in vitro. In agreement with previous reports
(Dezzutti et al., 2011; Wira et al., 2005; Fichorova and
Anderson, 1999; Bard et al., 2002), our results demon-
strated that endocervical secretions were enriched with
immune mediators compared with vaginal secretions.
Additionally, enhanced HIV infectivity was found in endo-
cervical  secretions from C. trachomatis-infected women
compared with post-treatment samples. These results
suggest the possibility of immunological compartmen-
talization in the lower genital tract and indicate that
endocervical secretions may  serve as a valuable source for
searching  for inﬂammation biomarkers and for predict-
ing  the risk of HIV transmission in C. trachomatis-infected
asymptomatic subjects. Similar ﬁndings could likely be
observed  in the context of other STI co-infections, particu-
larly  those that target the endocervix and warrant further
investigation as we search for appropriate biomarkers for
predicting  HIV transmission and for developing safe and
protective microbicides.
It  is quite likely that the differential proﬁle of immune
mediators noted between the endocervical and vaginal
secretions is because the endocervix is the preferential
site of infection for C. trachomatis. Our results also sug-
gest  that mediators induced by C. trachomatis infection in
the  endocervix may  also, however, subsequently activate
and  amplify a more global, but distinct, response in the
lower  tract. This would likely occur via the natural gravita-
tional ﬂow of cytokine-containing endocervical secretions
that  could contribute to the activation of a distinct lower
tract  immune response via their interaction with lower
tract  epithelial cells. Pretreatment levels of G-CSF, IL-1,
and  RANTES in endocervical secretions, IFN- and TNF-
in  vaginal secretions, and IFN-, IL-1, and MIP-1 in CVL
were higher than post-treatment levels. Although levels of
these  immune mediators differed as well within different
regions of the lower genital tract, IFN-, RANTES and MIP-
1  are involved in Th1 responses (Luther and Cyster, 2001).
These  results are consistent with a previous prospective
analysis of levels of IL-2 and IL-12 in adolescents at high
risk  of STIs, which demonstrated Th1-associated cytokine
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Table  6
The  effect of cervico-vaginal ﬂuid on HIV infectivity.
Pre-treatment median (IQR), RLU Post-treatment median (IQR), RLU P value
Endocervical 18,166 (7088.5–90,918) 12,710.7 (1548–33,467) 0.002
Vaginal 96,049 (47,081–188,615) 115,850.5 (49,672–568,200) 0.489
CVL  37,599 (11,156–80,547) 54,980 (23,606–290,847) 0.208
quartileThe median HIV infection is expressed as relative light units, RLU (inter
independent  experiments was 12,6721 ± 47898.
responses during C. trachomatis infection (Wang et al.,
2005).  We  did not include IL-2 and IL-12 in this study
because of their low abundance in endocervical secretions
during an initial screening (data not shown). We  specu-
late  that low levels of IL-2 and IL-12 observed in that study
might  be a consequence of the duration of asymptomatic
chlamydial infection, patient selection criteria, and a small
sample  size compared with the study by Wang et al. (2005).
We  also speculate that the relatively low levels of IFN-
found in endocervical pretreatment samples might also be
a  consequence of the young age of these patients, as higher
concentrations of IFN-, a key cytokine in the resolution
of chlamydial infection, is associated with older age (Arno
et  al., 1990) and with recurrent infection (Agrawal et al.,
2007).
Maxion and Kelly (2002) demonstrated differential gene
expression of chemokines within anatomically distinct
regions of the female genital tract in mice infected with the
C.  trachomatis mouse pneumonitis biovar, C. muridarum. In
this  murine model, induction of CXCL9, IP-10, and RANTES
in  oviducts (upper genital tract) was much higher than
that  in the cervicovaginal region (lower genital tract) in
response to C. muridarum. Additionally, higher numbers of
CD4+  T cells were recruited to the upper genital tract than
to  the lower genital tract during chlamydial infection in
mice  (Kelly et al., 2000). In this human study, we observed
elevated levels of chemokines such as RANTES and MIP-
1  in endocervical secretions from C. trachomatis-positive
women compared with post-treatment samples. Induction
of  these chemokines may  contribute to the recruitment
of endocervical CD4+ T cells found in women with C. tra-
chomatis infection (Mittal et al., 2004; Ficarra et al., 2008;
Levine et al., 1998). In the rhesus macaque model, in
response to SIV challenges, the endocervical epithelium
produces MIP-3 to recruit pDCs that produce cytokines
(IFN) and chemokines (MIP-1 and MIP-1), leading to
the  migration of CCR5-expressing cells such as CD4+ T
cells,  which are SIV/HIV target cells (Li et al., 2009). Simi-
larly,  in asymptomatic C. trachomatis-positive women, local
inﬂammation, soluble endocervical factors, and increased
HIV  target cells in the genital mucosa may  facilitate HIV
transmission.
We  observed an increase in HIV infectivity of endo-
cervical secretions from C. trachomatis-positive women
compared with convalescent samples. This association
between C. trachomatis and in vitro HIV infectivity was
not  found in vaginal secretions or CVL. The HIV infectiv-
ity assay in this study was designed to assess factors in the
clinical  samples that may  modulate the early steps of HIV
infection, including attachment and entry. The cytokines
and chemokines in the clinical specimens were in contact range (IQR)). The average RLU ± SD for HIV infection in PBS from four
with  HIV target cells for only two  hours during viral adsorp-
tion.  Additionally, a freeze–thaw process, which cannot be
avoided  in a longitudinal study, may  reduce the activities
of  cytokines and chemokines at low concentrations in clini-
cal  samples. Thus, it is unlikely that the immune mediators
measured in this study had a direct impact on the early
steps of HIV infection. For example, the levels of RANTES
and MIP-1, known HIV entry inhibitors by competing for
CCR5  co-receptor, were elevated in pre-treatment sam-
ples;  however, these two chemokines were unlikely to
have  any effect in the in vitro infectivity assay because
of their low concentrations. It remains to be determined
whether induction of a HIV-enhancing factor(s) or down-
regulation of HIV inhibitory factor(s) by C. trachomatis led
to  an increase in HIV infectivity in pretreatment samples.
Sex  hormones play an important role in innate immu-
nity in the female genital tract (Wira et al., 2010; Hel et al.,
2010).  We  observed that changes in endocervical IP-10
and  MCP-1 expression were associated with the use of
hormonal contraception in C. trachomatis-positive women
post-treatment. This association was not found in vaginal
secretions and CVL, despite the fact that these lower gen-
ital  tract regions are responsive to sex hormones (Wira
et  al., 1999). Modulation of cytokines and chemokines
in response to sex hormones has been primarily stud-
ied  in the upper genital tract. In women after estradiol
treatment, progesterone up-regulates IL-8 and MCP-1 in
endometrial epithelium in the pre-receptive (day 18) and
receptive (day 21) periods of the secretory phase of the
menstrual cycle (Caballero-Campo et al., 2002). However,
estrogen, but not progesterone, suppresses Toll-like recep-
tor  (TLR3)-mediated IL-6, IL-8, and IP-10 production in
an  endometrial cell line (RL95-2) following poly I-C stim-
ulation  (Lesmeister et al., 2005). Interestingly, in a new
polarized endocervical A2EN epithelial cell model, neither
estradiol nor progesterone/estradiol affects constitutive
cytokine/chemokine production, although the combina-
tion  of progesterone/estradiol blocks poly I:C-induced
secretion of MIP-1, RANTES, IP-10, TNF, IL-6, CXCL8,
and G-CSF (Buckner et al., 2011b). It is not clear whether
the chemokines in endocervical secretions are produced
by  endocervical epithelial cells or by immune cells at this
mucosal site (Wira et al., 2010). Our results demonstrate,
however, that hormone contraception modulates the level
of  some chemokines in the endocervix.
We observed differential proﬁles of immune mediators
and in vitro HIV infectivity between endocervical and vagi-
nal  secretions in this longitudinal pilot study. In addition,
the concentrations of these immune mediators, with the
exception of IL-1 and MIP-1, were 10- to 100-fold higher
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VL. The lower concentrations of mediators in CVL may
e  due to the larger volume sample collection (10 ml)  in
omparison to the volume for endocervical and vaginal sec-
etions  (0.7 ml). The methods of normalizing cervicovaginal
pecimens are still a somewhat debatable topic in the ﬁeld.
n  this study, we controlled the volume of endocervical
nd vaginal samples and did not normalize the levels of
mmune  mediators based on concentrations of total protein
r  human albumin because of the inﬂux of immune cells or
roteins  to the endocervix that occurs during C. trachomatis
nfection (Agrawal et al., 2007; Ficarra et al., 2008; Persson
t  al., 1990). Interestingly, we observed a decrease in HIV
nfectivity in endocervical secretions compared with CVL
r  vaginal secretions regardless of the treatment (Table 6),
hich  could be a consequence of the overall higher con-
entrations of immune mediators including HIV inhibitory
actors in the endocervix. A recent ex vivo study indicates
hat  higher HIV replication occurs in cervical tissues than
n  vaginal tissues from healthy women, possibly because
f  the availability of HIV target cells in different tissues
Dezzutti et al., 2013). Although the in vitro HIV infectiv-
ty  assay and the ex vivo HIV infection of tissue biopsies
re two distinct methods of addressing the effect of sol-
ble  factors or target cells in different tissues on HIV
nfection, both studies support anatomical sites having a
ifferential  impact on HIV infection. Taken together, it is
mportant to consider anatomical sites and local sampling
ethodology in the interpretation of mucosal responses.
dditionally, endocervical specimens should be included in
tudies  that investigate genital mucosal responses involved
n  HIV spread in the setting of C. trachomatis, and other
ndocervical co-infections.
A  recent large-scale study demonstrated that asymp-
omatic laboratory-diagnosed STIs, but not symptomatic
TI diagnosis (vaginal discharge) were associated with an
ncreased  susceptibility to HIV acquisition (Mlisana et al.,
012),  highlighting the importance of identifying asymp-
omatic STIs and treatment for HIV prevention. Mlisana
t  al. (2012) have shown a weak correlation between ele-
ated  levels of inﬂammatory cytokines IL-1, IL-6, IL-8,
nd  sCD40L in CVL and an increased risk of HIV infection.
imilarly, we found an increase in immune mediators in
emale  genital secretions and enhancement of in vitro HIV
nfectivity in asymptomatic C. trachomatis-positive women
hat  decreased after antibiotic treatment. Taken together,
hese results suggest that the effective control of STIs
ight play an important role in the success of HIV pre-
ention.
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